Rifaximin

Rifaximin, a gastrointestinal-selective antibiotic, binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis. Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL) [1][2].

Product Specifications

CAS Number

[80621-81-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Rifaximin.html

Purity

99.64

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C1C2=C(O[C@@]1(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@@H](O)[C@@H](C)/C=C/C=C(C)\C3=O)C)O)C)OC(C)=O)C)OC)C)C(C)=C(O)C4=C2C5=C(C(N3)=C4O)N6C(C=C(C)C=C6)=N5

Molecular Formula

C43H51N3O11

Molecular Weight

785.88

Precautions

H302, H315, H319, H335

References & Citations

[1]Veronica Ojetti, et al. Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol. 2009 Jun;5 (6) :675-82.|[2]Giuseppe Esposito, et al. Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. Int J Oncol. 2016 Aug;49 (2) :639-45.|[3]Stefano Fiorucci, et al.Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66 (4) :246-56.